Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet the following inclusion criteria to be eligible for the study.~* Subject can provide written informed consent and is willing to comply with study procedures.~* Subject is at least 18 years of age.~* Subject has focal epilepsy with classifiable seizures according to the International Classification of Epileptic Seizures, 1981.11~* Subject is deemed to be an appropriate candidate for LCM adjunctive therapy.~* Subject has been maintained on a stable dose of 1 or 2 marketed AEDs for at least 4 weeks.~Exclusion Criteria:~Subjects must meet the following exclusion criteria to be eligible for the study.~* Subject has a history of a moderate or severe sleep apnea (apnea-hypopnea index \[AHI\] \> 15), severe insomnia (habitual sleep duration \< 4 hours) or narcolepsy.~* Subject has a score on the Sleep Apnea Scale of the Sleep Disorders Questionnaire (SA/SDQ) at screening of 32 or higher (female) and 36 or higher (male).~* Subject is currently participating or has participated within the last 2 months in a trial of an investigational drug or experimental device.~* Subject has seizures or seizures clusters that are not quantifiable.~* Subject has 6 or more seizures (excluding auras) in the 2-week Baseline Phase.~* Subject has a medical condition that could reasonably be expected to interfere with drug absorption, distribution, metabolism or excretion.~* Subject has any medical or psychiatric condition, which in the opinion of the investigator, could jeopardize the subject's health or would compromise the - Subject has a history of alcohol or drug abuse within the previous 2 years.~* Subject has an acute or sub-acutely progressive central nervous system disease.~* Subject is pregnant, breastfeeding or of childbearing age and not surgically sterile or practicing an acceptable form of contraception (barrier contraception, surgically sterilized, IUD, abstinence) for the duration of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): None
- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).